These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31784089)

  • 1. Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice.
    Yang J; Liu L; Yang X; Duan Y; Zeng P; Yang S; Ma C; Li X; Han J; Chen Y
    Biochem Biophys Res Commun; 2020 Feb; 522(2):512-517. PubMed ID: 31784089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
    Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
    Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development.
    van der Stoep M; Li Z; Calpe-Berdiel L; van der Sluis RJ; Saleh P; McKinnon HJ; Smit MJ; Korporaal SJ; Van Berkel TJ; Van Eck M; Hoekstra M
    Biochem Pharmacol; 2013 Dec; 86(11):1594-602. PubMed ID: 24095721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transport-An anti-atherogenic function of ERK1/2 inhibition.
    Zhang L; Chen Y; Yang X; Yang J; Cao X; Li X; Li L; Miao QR; Hajjar DP; Duan Y; Han J
    Biochim Biophys Acta; 2016 Sep; 1861(9 Pt A):1180-1191. PubMed ID: 27365310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anionic nanoliposomes reduced atherosclerosis progression in Low Density Lipoprotein Receptor (LDLR) deficient mice fed a high fat diet.
    Krishna SM; Moxon JV; Jose RJ; Li J; Sahebkar A; Jaafari MR; Hatamipour M; Liu D; Golledge J
    J Cell Physiol; 2018 Oct; 233(10):6951-6964. PubMed ID: 29741759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting macrophage liver X receptors by hydrogel-encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis.
    Ma C; Feng K; Yang X; Yang Z; Wang Z; Shang Y; Fan G; Liu L; Yang S; Li X; Han J; Duan Y; Chen Y
    Br J Pharmacol; 2021 Apr; 178(7):1620-1638. PubMed ID: 33506494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317.
    Peng D; Hiipakka RA; Reardon CA; Getz GS; Liao S
    Atherosclerosis; 2009 Mar; 203(1):59-66. PubMed ID: 18639878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice.
    Peng D; Hiipakka RA; Xie JT; Dai Q; Kokontis JM; Reardon CA; Getz GS; Liao S
    Br J Pharmacol; 2011 Apr; 162(8):1792-804. PubMed ID: 21232031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size.
    Okazaki H; Goldstein JL; Brown MS; Liang G
    J Biol Chem; 2010 Feb; 285(9):6801-10. PubMed ID: 20037162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor growth by U0126 is associated with induction of interferon-γ production.
    Ma X; Wang Q; Liu Y; Chen Y; Zhang L; Jiang M; Li X; Xiang R; Miao RQ; Duan Y; Han J
    Int J Cancer; 2015 Feb; 136(4):771-83. PubMed ID: 24947959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.
    Dong Y; Xu Z; Zhang Z; Yin X; Lin X; Li H; Zheng F
    J Mol Endocrinol; 2017 Apr; 58(3):141-154. PubMed ID: 28258092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
    Eussen SR; Rompelberg CJ; Andersson KE; Klungel OH; Hellstrand P; Oste R; van Kranen H; Garssen J
    Pharmacol Res; 2011 Jul; 64(1):36-43. PubMed ID: 21371558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK1/2 inhibitor inhibits neointima formation by activating miR-126-3p/ C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 4 (CXCR4) axis.
    Yan Y; Zhu M; Ma J; He X; Yang X; Xu H; Jiang M; Zhang S; Duan Y; Han J; Chen Y
    Bioengineered; 2022 Apr; 13(4):11214-11227. PubMed ID: 35485167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (
    Burke AC; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Barrett PHR; Newton RS; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1178-1190. PubMed ID: 29449335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
    Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-phenylbutyrate and valproate treatment attenuates the progression of atherosclerosis and stabilizes existing plaques.
    Huang A; Young TL; Dang VT; Shi Y; McAlpine CS; Werstuck GH
    Atherosclerosis; 2017 Nov; 266():103-112. PubMed ID: 29024862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salusin-α attenuates hepatic steatosis and atherosclerosis in high fat diet-fed low density lipoprotein receptor deficient mice.
    Tang K; Wang F; Zeng Y; Chen X; Xu X
    Eur J Pharmacol; 2018 Jul; 830():76-86. PubMed ID: 29704496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice.
    Out R; Hoekstra M; Hildebrand RB; Kruit JK; Meurs I; Li Z; Kuipers F; Van Berkel TJ; Van Eck M
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2295-300. PubMed ID: 16857950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.